This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Effect of methylphenidate on attention in apathetic AD patients in a randomized, placebo-controlled trial


Lanctôt, Krista L., Chau, Sarah A., Herrmann, Nathan, Drye, Lea T., Rosenberg, Paul B., Scherer, Roberta W., Black, Sandra E., Vaidya, Vijay, Bachman, David L., Mintzer, Jacobo E.


International Psychogeriatrics / IPA, Volume: 26, No.: 2, Pages.: 239-246

Year of Publication



Background: Little is known about the effect of methylphenidate (MPH) on attention in Alzheimer’s disease (AD). MPH has shown to improve apathy in AD, and both apathy and attention have been related to dopaminergic function. The goal was to investigate MPH effects on attention in AD and assess the relationship between attention and apathy responses.; Methods: MPH (10 mg PO twice daily) or placebo was administered for six weeks in a randomized, double-blind trial in mild-to-moderate AD outpatients with apathy (Neuropsychiatric Inventory (NPI) Apathy ≥ 4). Attention was measured with the Wechsler Adult Intelligence Scale–Digit Span (DS) subtest (DS forward, selective attention) and apathy with the Apathy Evaluation Scale (AES). A mixed effects linear regression estimated the difference in change from baseline between treatment groups, defined as δ (MPH (DS week 6-DS baseline)) – (placebo (DS week 6-DS baseline)).; Results: In 60 patients (37 females, age = 76 ± 8, Mini-Mental State Examination (MMSE) = 20 ± 5, NPI Apathy = 7 ± 2), the change in DS forward (δ = 0.87 (95% CI: 0.06-1.68), p = 0.03) and DS total (δ = 1.01 (95% CI: 0.09-1.93), p = 0.03) favored MPH over placebo. Of 57 completers, 17 patients had improved apathy (≥3.3 points on the AES from baseline to end point) and 40 did not. There were no significant associations between AES and NPI Apathy with DS change scores in the MPH, placebo, AES responder, or non-responder groups. DS scores did not predict apathy response to MPH treatment.; Conclusion: These results suggest MPH can improve attention and apathy in AD; however, the effects appear independent in this population.;

Bibtex Citation

@article{Lanct_t_2013, doi = {10.1017/s1041610213001762}, url = {}, year = 2013, month = {oct}, publisher = {Cambridge University Press ({CUP})}, volume = {26}, number = {02}, pages = {239--246}, author = {Krista L. Lanct{^{o}}t and Sarah A. Chau and Nathan Herrmann and Lea T. Drye and Paul B. Rosenberg and Roberta W. Scherer and Sandra E. Black and Vijay Vaidya and David L. Bachman and Jacobo E. Mintzer}, title = {Effect of methylphenidate on attention in apathetic {AD} patients in a randomized, placebo-controlled trial}, journal = {Int. Psychogeriatr.} }


administration & dosage, adverse effects, aged, aged, 80 and over, alzheimer disease, apathy, attention, central nervous system stimulants, diagnosis, double-blind method, drug effects, drug monitoring, drug therapy, female, humans, male, methods, methylphenidate, neuropsychological tests, psychiatric status rating scales, psychology, ritalin, treatment outcome

Countries of Study


Types of Dementia

Alzheimer’s Disease

Types of Study

Randomised Controlled Trial

Type of Outcomes

Behaviour, Cognition


Hospital Outpatient Care

Type of Interventions

Pharmaceutical Interventions